Literature DB >> 12792489

Encephalocraniocutaneous lipomatosis: case report and review of the literature.

Zina Almer1, Victoria Vishnevskia-Dai, David Zadok.   

Abstract

PURPOSE: Encephalocraniocutaneous lipomatosis is a congenital neurocutaneous syndrome characterized by lipomatous craniofacial hamartomas. The most common ocular manifestation is epibulbar choristoma, but many additional eye anomalies may be present.
METHODS: To our knowledge, this is the first reported case with bilateral aniridia. We report a case of a boy affected by this syndrome and review the literature.
CONCLUSION: Regarding this case, we suggest adding aniridia to the possible ocular anomalies in this syndrome.

Entities:  

Mesh:

Year:  2003        PMID: 12792489     DOI: 10.1097/00003226-200305000-00023

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  4 in total

1.  Encephalocraniocutaneous lipomatosis: a rare case with development of diffuse leptomeningeal lipomatosis during childhood.

Authors:  Ryan K L Lee; Phoenix P Y Lui; Cina S L Tong; Winnie C W Chu
Journal:  Pediatr Radiol       Date:  2011-06-30

2.  Hemimegalencephaly with Facial Congenital Infiltrating Lipomatosis in a Child.

Authors:  Adrián Santana-Ramirez; Felipe Farias-Serratos; José Sanchez-Corona; Gema Castañeda-Cisneros; Nadia M Farias-Serratos
Journal:  Iran J Public Health       Date:  2014-12       Impact factor: 1.429

Review 3.  Congenital upper eyelid coloboma: embryologic, nomenclatorial, nosologic, etiologic, pathogenetic, epidemiologic, clinical, and management perspectives.

Authors:  Hatem A Tawfik; Mohamed H Abdulhafez; Yousef A Fouad
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Jan-Feb       Impact factor: 1.746

4.  Encephalocraniocutaneous lipomatosis (Haberland's syndrome): a case report of a neurocutaneous syndrome and a review of the literature.

Authors:  Giovanna Negrisoli Koishi; Mauricio Yoshida; Nivaldo Alonso; Hamilton Matushita; Dov Goldenberg
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.